IMUNON INC (IMNN)
US15117N6022 - Common Stock
IMNN gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 568 industry peers in the Biotechnology industry. While IMNN seems to be doing ok healthwise, there are quite some concerns on its profitability. IMNN does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
In the past year IMNN has reported negative net income.
IMNN had a negative operating cash flow in the past year.
IMNN had negative earnings in each of the past 5 years.
In the past 5 years IMNN always reported negative operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of -89.03%, IMNN is doing worse than 72.21% of the companies in the same industry.
Looking at the Return On Equity, with a value of -145.77%, IMNN is doing worse than 63.72% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -89.03% | ||
| ROE | -145.77% | ||
| ROIC | N/A |
ROA(3y)-66.24%
ROA(5y)-59.99%
ROE(3y)-101.8%
ROE(5y)-107.31%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
IMNN does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
IMNN does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, IMNN has more shares outstanding
Compared to 5 years ago, IMNN has more shares outstanding
There is no outstanding debt for IMNN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
IMNN has an Altman-Z score of -26.49. This is a bad value and indicates that IMNN is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of IMNN (-26.49) is worse than 90.09% of its industry peers.
There is no outstanding debt for IMNN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -26.49 |
ROIC/WACCN/A
WACC31.2%
2.3 Liquidity
A Current Ratio of 2.47 indicates that IMNN has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 2.47, IMNN is doing worse than 71.15% of the companies in the same industry.
IMNN has a Quick Ratio of 2.47. This indicates that IMNN is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 2.47, IMNN is doing worse than 70.09% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.47 | ||
| Quick Ratio | 2.47 |
3. Growth
3.1 Past
IMNN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 42.20%, which is quite impressive.
Looking at the last year, IMNN shows a very negative growth in Revenue. The Revenue has decreased by -100.00% in the last year.
EPS 1Y (TTM)42.2%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%8.11%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
The Earnings Per Share is expected to grow by 13.21% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y20.81%
EPS Next 2Y21.68%
EPS Next 3Y16.5%
EPS Next 5Y13.21%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for IMNN. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for IMNN. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
IMNN's earnings are expected to grow with 16.50% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y21.68%
EPS Next 3Y16.5%
5. Dividend
5.1 Amount
IMNN does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
IMUNON INC
NASDAQ:IMNN (12/20/2024, 4:57:49 PM)
After market: 0.82 -0.01 (-1.2%)0.83
-0.02 (-2.83%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners7.01%
Inst Owner Change172.45%
Ins Owners4.4%
Ins Owner Change7.84%
Market Cap12.04M
Analysts82
Price Target13.46 (1521.69%)
Short Float %5.15%
Short Ratio3.98
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)10.35%
Min EPS beat(2)-24.34%
Max EPS beat(2)45.04%
EPS beat(4)2
Avg EPS beat(4)8.84%
Min EPS beat(4)-24.34%
Max EPS beat(4)45.04%
EPS beat(8)3
Avg EPS beat(8)-13.98%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-7.04%
PT rev (3m)25.71%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)4.51%
EPS NY rev (3m)0.25%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.9 | ||
| P/tB | 0.9 | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.89
EYN/A
EPS(NY)-1.13
Fwd EYN/A
FCF(TTM)-1.34
FCFYN/A
OCF(TTM)-1.31
OCFYN/A
SpS0
BVpS0.92
TBVpS0.92
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -89.03% | ||
| ROE | -145.77% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-66.24%
ROA(5y)-59.99%
ROE(3y)-101.8%
ROE(5y)-107.31%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 182.05% | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.47 | ||
| Quick Ratio | 2.47 | ||
| Altman-Z | -26.49 |
F-Score2
WACC31.2%
ROIC/WACCN/A
Cap/Depr(3y)87.77%
Cap/Depr(5y)62.93%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)42.2%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%8.11%
EPS Next Y20.81%
EPS Next 2Y21.68%
EPS Next 3Y16.5%
EPS Next 5Y13.21%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y15.61%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y16.78%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y17.76%
OCF growth 3YN/A
OCF growth 5YN/A